AmiLyfe ORS solution offers huge potential to save more lives
amid global diarrhea crisis, as seen in study recently published in
The Lancet family of journals.
NORWOOD,
Mass., July 10, 2024 /PRNewswire-PRWeb/ --
AmiLyfe BioScience LLC made the biggest oral rehydration solution
(ORS) breakthrough in 23 years. As documented in a study of 312
children recently published in The Lancet family of
journals, the Amilyfe formulation proved to be both safe and
effective. The ORS also showed a trend towards a shorter duration
of diarrhea by a clinically important 7 hours and lowered stool
volume in infants and children aged 6–36 months suffering from
diarrhea. AmiLyfe achieved those results by using its trademarked
artificial intelligence (AI) platform called Maestro™ to accelerate
the development of its ORS formulations using a precise combination
of natural amino acids instead of glucose, noting that previous
studies with random amino acids yielded no benefit.
"AmiLyfe's mission is both simple and
profound. We are here to revolutionize health and wellness." -
Stephen Gatto
The need for ORS advancement is urgent. There are 1.7 billion
cases of diarrhea every year globally, according to the World
Health Organization (WHO). Diarrhea dehydrates the body. In fact,
says WHO, it's the leading cause of malnutrition in children under
5, and it kills 450,000 children worldwide under the age of 5.
ORS — heralded among the top 50 medical discoveries in history —
has saved millions of lives. It is even preferred over intravenous
(IV) therapy for treating mild to moderate dehydration due to its
significant cost savings, ease of administration, and effectiveness
in replenishing essential electrolytes.
AmiLyfe's next-generation ORS represents a significant leap
forward by utilizing eight times the number of cellular
transporters, which facilitate a superior rehydration process
compared to glucose. Moreover, no serious adverse side effects were
observed in the study including hypoglycemia or hyponatremia in any
of the participating children during their use of non-glucose,
amino acid-based ORS.
"A formula that addresses diarrhea and malnutrition in children
would be a lifesaver in many cases in the developing world," said
Dr. Olivier Fontaine, former medical
officer specializing in childhood diarrhea at the World Health
Organization. "What AmiLyfe has achieved is very significant. They
developed the only glucose-free ORS to have shown efficacy in
rehydrating a child suffering from diarrhea."
The science behind ORS took a giant leap forward due to
AmiLyfe's work. Others have unsuccessfully tried using amino acid
in ORS before, but AmiLyfe honed its innovative ultra-hydrating
technology over the last 10 years at the University of Florida and through groundbreaking
R&D for NASA/NSBRI to protect astronauts from the adverse GI
effects of ionizing radiation during long duration space
travel.
"Using Maestro, we have identified over 50 biofunctional
formulations targeting gut health, hydration, respiratory disease
and skin care — all of which have been clinically studied and
proven to provide meaningful health benefits," said AmiLyfe
Chairman and CEO Stephen Gatto. "We
are striving to save even more lives by using Maestro to accelerate
research into the cellular dynamics of natural amino acids,
unearthing critical insights into their impact on essential
physiological functions such as secretion, absorption, barrier
integrity, and proliferation."
A clinical study at Loughborough
University showed that AmiLyfe's ORS demonstrated superior
electrolyte recovery compared to leading glucose-based ORS.
- AmiLyfe's ORS was faster and provided a more complete sodium
and chloride deficit replacement than Pedialyte and Pedialyte
Zero.
- AmiLyfe's formulation also provided a faster and more complete
potassium deficit replacement than Pedialyte Zero.
A 2019 study published in the journal Nutrients ("Osmolality of
Commercially Available Oral Rehydration Solutions: Impact of Brand,
Storage Time, and Temperature") found that AmiLyfe's product
(enterade®) "was the only pre-mixed beverage" that stayed within
the recommended osmolality range where the most optimal rate of net
fluid absorption occurs.
Furthermore, AmiLyfe's amino acid platform has recently been
shown to improve intestinal permeability in a study of Bangladeshi
children suffering from chronic intestinal inflammation due to
recurrent dysentery exposure. This improvement can enhance nutrient
absorption, potentially leading to better growth and development
for malnourished children.
"AmiLyfe's mission is both simple and profound," added Gatto.
"We are here to revolutionize health and wellness."
Additionally, AmiLyfe's amino acid platform has recently shown
to help improve the gut health of Bangladeshi children suffering
from chronic intestinal inflammation caused by frequent dysentery
and associated environmental enteropathies. This improvement can
help their bodies absorb nutrients better, which can lead to better
growth and development for these malnourished children.
About AmiLyfe BioScience LLC
AmiLyfe Bioscience harnesses the transformative power of bioactives
in the form of natural amino acids to enhance and restore human
health. Through innovative biotechnology and our advanced AI
platform, Maestro™, we discover and develop biofunctional
formulations that address specific health and wellness needs. We
create scientifically validated, IP-protected products that improve
the quality of life for individuals worldwide, while promoting
sustainability and responsible innovation. For more information,
please visit AmiLyfe.com.
Media Contact
Kathy Silverstein, On The Marc
Media, 4109632345, kathleen@onthemarcmedia.com,
https://onthemarcmedia.com/
View original
content:https://www.prweb.com/releases/amilyfe-bioscience-llc-achieves-first-major-ors-solution-breakthrough-in-23-years-302193568.html
SOURCE AmiLyfe BioScience LLC